Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex
Open Access
- 8 December 2022
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-15
Abstract
The lipid nanoparticle (LNP)-formulated mRNA vaccines BNT162b2 and mRNA-1273 are a widely adopted multi vaccination public health strategy to manage the COVID-19 pandemic. Clinical trial data has described the immunogenicity of the vaccine, albeit within a limited study time frame. Here, we use a within-host mathematical model for LNP-formulated mRNA vaccines, informed by available clinical trial data from 2020 to September 2021, to project a longer term understanding of immunity as a function of vaccine type, dosage amount, age, and sex. We estimate that two standard doses of either mRNA-1273 or BNT162b2, with dosage times separated by the company-mandated intervals, results in individuals losing more than 99% humoral immunity relative to peak immunity by 8 months following the second dose. We predict that within an 8 month period following dose two (corresponding to the original CDC time-frame for administration of a third dose), there exists a period of time longer than 1 month where an individual has lost more than 99% humoral immunity relative to peak immunity, regardless of which vaccine was administered. We further find that age has a strong influence in maintaining humoral immunity; by 8 months following dose two we predict that individuals aged 18–55 have a four-fold humoral advantage compared to aged 56–70 and 70+ individuals. We find that sex has little effect on the immune response and long-term IgG counts. Finally, we find that humoral immunity generated from two low doses of mRNA-1273 decays at a substantially slower rate relative to peak immunity gained compared to two standard doses of either mRNA-1273 or BNT162b2. Our predictions highlight the importance of the recommended third booster dose in order to maintain elevated levels of antibodies.Keywords
Funding Information
- National Research Council Canada
- Natural Sciences and Engineering Research Council of Canada
This publication has 104 references indexed in Scilit:
- Sensitivity analysis of infectious disease models: methods, advances and their applicationJournal of The Royal Society Interface, 2013
- Age Affects Quantity but Not Quality of Antibody Responses after Vaccination with an Inactivated Flavivirus Vaccine against Tick-Borne EncephalitisPLOS ONE, 2012
- Age effects on B cells and humoral immunity in humansAgeing Research Reviews, 2011
- Interleukins, from 1 to 37, and interferon-γ: Receptors, functions, and roles in diseasesJournal of Allergy and Clinical Immunology, 2011
- IL-10 production by CD4+ effector T cells: a mechanism for self-regulationMucosal Immunology, 2010
- Cytokines, Inflammation, and PainInternational Anesthesiology Clinics, 2007
- ANTIGEN-SPECIFIC MEMORY B CELL DEVELOPMENTAnnual Review of Immunology, 2005
- T-cell priming by dendritic cells in lymph nodes occurs in three distinct phasesNature, 2004
- In vivo expression of interleukin‐8, and regulated on activation, normal, T‐cell expressed, and secreted, by human germinal centre B lymphocytesImmunology, 2003
- A Comparison of Three Methods for Selecting Values of Input Variables in the Analysis of Output From a Computer CodeTechnometrics, 2000